Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels

British Journal of Pharmacology

Volumn 156, Issue 6, 2009, Pages 941-951

  Chen, Wen Qiang ^a   Zhong, Lin ^b   Zhang, Lei ^a   Ji, Xiao Ping ^a   Zhang, Mei ^a   Zhao, Yu Xia ^a   Zhang, Cheng ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Atherosclerosis; Inflammation; Rapamycin; Vulnerable plaque

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RAPAMYCIN; SIMVASTATIN; STROMELYSIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; LIPID;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ECHOGRAPHY; ENDOTHELIUM INJURY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; ANIMAL; ATHEROSCLEROSIS; BLOOD; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANIMALS; AORTA, ABDOMINAL; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; INFLAMMATION; INTERLEUKINS; LIPIDS; MATRIX METALLOPROTEINASE 1; P-SELECTIN; RABBITS; SIROLIMUS;

EID: 67650602355     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00102.x     Document Type: Article

References (35)

1. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE et al. (1998). Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 : 2433 2444.
2. Armstrong EJ, Morrow DA, Sabatine MS (2006). Inflammatory biomarkers in acute coronary syndromes. Part I: introduction and cytokines. Circulation 113 : e72 e75.
3. Burke SE, Lubbers NL, Chen YW, Hsieh GC, Mollison KW, Luly JR et al. (1999). Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 33 : 829 835.
4. Carr SC, Farb A, Pearce WH, Virmani R, Yao JS (1997). Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 122 : 757 763.
5. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V (2004). Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 172 : 31 38.
6. Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A et al. (2008). Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86 : 245 250.
7. Chen WQ, Zhang M, Ji XP, Ding SF, Zhao YX, Chen YG et al. (2007a). Usefulness of high frequency vascular ultrasound imaging and serum inflammatory markers to predict plaque rupture in patients with stable and unstable angina pectoris. Am J Cardiol 100 : 1341 1346.
8. Chen WQ, Zhang L, Liu YF, Chen L, Ji XP, Zhang M et al. (2007b). Prediction of atherosclerotic plaque ruptures with high frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 293 : H2836 H2844.
9. Danner S, Sigrist S, Moreau F, Mandes K, Vodouhé C, Langlois A et al. (2008). Influence of rapamycin on rat macrophage viability and chemotaxis toward allogenic pancreatic islet supernates. Transplant Proc 40 : 470 472.
10. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al. (2003). Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 : 847.
11. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R (2002). Oral everolimus inhibits in-stent neointimal growth. Circulation 106 : 2379 2384.
12. Gregory CR, Huie P, Billingham ME, Morris RE (1993). Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55 : 1409 1418.
13. Kovanen PT, Mayranpaa M, Lindstedt KA (2005). Drug therapies to prevent coronary plaque rupture and erosion: present and future. Handb Exp Pharmacol 170 : 745 776.
14. Libby P, Aikawa M (2002). Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8 : 1257 1262.
15. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 : 402 408.
16. Martinet W, Verheye S, De Meyer GR (2007). Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3 : 241 244. (Pubitemid 46752686)
17. Marx SO, Marks AR (2001). Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 : 852 855.
18. Mintz GS, Nissen SE, Anderson WD, Rosenfield K, Bailey S, Siegel R et al. (2001). American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of Intravascular Ultrasound Studies (IVUS). J Am Coll Cardiol 37 : 1478 1492.
19. Mita A, Ricordi C, Miki A, Barker S, Haertter R, Hashikura Y et al. (2008). Anti-proinflammatory effects of sirolimus on human islet preparations. Transplantation 86 : 46 53.
20. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. (2003). Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 : 1315 1323.
21. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J (2008). Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 198 : 39 48.
22. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J et al. (2003). From vulnerable plaque to vulnerable patient. A call for new definition and risk assessment strategies: part I. Circulation 108 : 1664 1672. (Pubitemid 37243650)
23. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC (2005). Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 37 : 1880 1884.
24. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R (2005). Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 46 : 481 486.
25. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. (2005). For the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 : 20 28.
26. Rodríguez AE, Rodríguez Alemparte M, Vigo CF, Fernández Pereira C, Llauradó C, Vetcher D et al. (2005). Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 91 : 1433 1437.
27. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C et al. (2006). ORAR II investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the prospective, randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 47 : 1522 1529.
28. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. (2001). Lack of neotintimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. Circulation 103 : 192 195.
29. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. (2001). Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 : 1188 1193.
30. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J et al. (1998). Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18 : 369 378.
31. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP et al. (2007). Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49 : 706 715. (Pubitemid 46205042)
32. Waksman R, Pakala R, Burnett MS, Gulick CP, Leborgne L, Fournadjiev J et al. (2003). Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 4 : 34 38.
33. Waksman R, Ajani AE, Pichard AD, Torguson R Pinnow E, Canos D et al. (2004). Oral rapamune to inhibit restenos study. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 44 : 1386 1392.
34. Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A (2007). Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J 28 : 2720 2725.
35. Williams H, Johnson JL, Carson KG, Jackson CL (2002). Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 22 : 788 779.